325 related articles for article (PubMed ID: 15845617)
1. The inhibition of RANKL causes greater suppression of bone resorption and hypercalcemia compared with bisphosphonates in two models of humoral hypercalcemia of malignancy.
Morony S; Warmington K; Adamu S; Asuncion F; Geng Z; Grisanti M; Tan HL; Capparelli C; Starnes C; Weimann B; Dunstan CR; Kostenuik PJ
Endocrinology; 2005 Aug; 146(8):3235-43. PubMed ID: 15845617
[TBL] [Abstract][Full Text] [Related]
2. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
Kim YH; Kim GS; Jeong-Hwa B
Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid regulation of osteoclast differentiation and expression of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand, osteoprotegerin, and receptor activator of NF-kappaB in mouse calvarial bones.
Swanson C; Lorentzon M; Conaway HH; Lerner UH
Endocrinology; 2006 Jul; 147(7):3613-22. PubMed ID: 16614077
[TBL] [Abstract][Full Text] [Related]
5. Fibroblastic stromal cells express receptor activator of NF-kappa B ligand and support osteoclast differentiation.
Quinn JM; Horwood NJ; Elliott J; Gillespie MT; Martin TJ
J Bone Miner Res; 2000 Aug; 15(8):1459-66. PubMed ID: 10934644
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy.
Oyajobi BO; Anderson DM; Traianedes K; Williams PJ; Yoneda T; Mundy GR
Cancer Res; 2001 Mar; 61(6):2572-8. PubMed ID: 11289133
[TBL] [Abstract][Full Text] [Related]
7. Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells.
Kondo H; Guo J; Bringhurst FR
J Bone Miner Res; 2002 Sep; 17(9):1667-79. PubMed ID: 12211438
[TBL] [Abstract][Full Text] [Related]
8. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
9. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone.
Faucheux C; Horton MA; Price JS
J Bone Miner Res; 2002 Mar; 17(3):455-64. PubMed ID: 11874237
[TBL] [Abstract][Full Text] [Related]
10. Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength.
Kostenuik PJ
Curr Opin Pharmacol; 2005 Dec; 5(6):618-25. PubMed ID: 16188502
[TBL] [Abstract][Full Text] [Related]
11. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
[TBL] [Abstract][Full Text] [Related]
12. Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas.
Kumamoto H; Ooya K
J Oral Pathol Med; 2004 Jan; 33(1):46-52. PubMed ID: 14675140
[TBL] [Abstract][Full Text] [Related]
13. The high rate of bone resorption in multiple myeloma is due to RANK (receptor activator of nuclear factor-kappaB) and RANK Ligand expression.
Roux S; Mariette X
Leuk Lymphoma; 2004 Jun; 45(6):1111-8. PubMed ID: 15359989
[TBL] [Abstract][Full Text] [Related]
14. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases.
Hofbauer LC; Neubauer A; Heufelder AE
Cancer; 2001 Aug; 92(3):460-70. PubMed ID: 11505389
[TBL] [Abstract][Full Text] [Related]
15. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice.
Cui N; Nomura T; Noma H; Yokoo K; Takagi R; Hashimoto S; Okamoto M; Sato M; Yu G; Guo C; Shibahala T
Clin Cancer Res; 2005 Apr; 11(7):2713-9. PubMed ID: 15814653
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy.
Capparelli C; Kostenuik PJ; Morony S; Starnes C; Weimann B; Van G; Scully S; Qi M; Lacey DL; Dunstan CR
Cancer Res; 2000 Feb; 60(4):783-7. PubMed ID: 10706080
[TBL] [Abstract][Full Text] [Related]
17. Receptor activator of NF-kappa B ligand inhibition suppresses bone resorption and hypercalcemia but does not affect host immune responses to influenza infection.
Miller RE; Branstetter D; Armstrong A; Kennedy B; Jones J; Cowan L; Bussiere J; Dougall WC
J Immunol; 2007 Jul; 179(1):266-74. PubMed ID: 17579046
[TBL] [Abstract][Full Text] [Related]
18. Breast cancer cells interact with osteoblasts to support osteoclast formation.
Thomas RJ; Guise TA; Yin JJ; Elliott J; Horwood NJ; Martin TJ; Gillespie MT
Endocrinology; 1999 Oct; 140(10):4451-8. PubMed ID: 10499498
[TBL] [Abstract][Full Text] [Related]
19. Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption.
Kostenuik PJ; Shalhoub V
Curr Pharm Des; 2001 May; 7(8):613-35. PubMed ID: 11375772
[TBL] [Abstract][Full Text] [Related]
20. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.
Wittrant Y; Théoleyre S; Chipoy C; Padrines M; Blanchard F; Heymann D; Rédini F
Biochim Biophys Acta; 2004 Sep; 1704(2):49-57. PubMed ID: 15363860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
